Delaware Healthcare’s attractive, ordinary, and unappealing features continue to offset each other, and it remains a middling source of exposure to its target sector.
Delaware Healthcare A DLHAX
- NAV / 1-Day Return 25.92 / −0.77 %
- Total Assets 749.6 Mil
-
Adj. Expense Ratio
1.210%
- Expense Ratio 1.210%
- Distribution Fee Level Below Average
- Share Class Type Front Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.51%
- Turnover 3%
USD | NAV as of Apr 15, 2024 | 1-Day Return as of Apr 15, 2024, 11:48 PM GMT+0
Morningstar’s Analysis DLHAX
Will DLHAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 51.8
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 11.60 | 90.4 Mil | Healthcare |
Amgen Inc | 6.92 | 53.9 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 6.32 | 49.3 Mil | Healthcare |
UnitedHealth Group Inc | 4.81 | 37.5 Mil | Healthcare |
Merck & Co Inc | 4.81 | 37.5 Mil | Healthcare |
Elevance Health Inc | 4.05 | 31.6 Mil | Healthcare |
Pfizer Inc | 3.77 | 29.3 Mil | Healthcare |
Viking Therapeutics Inc | 3.26 | 25.4 Mil | Healthcare |
Boston Scientific Corp | 3.23 | 25.2 Mil | Healthcare |
Chugai Pharmaceutical Co Ltd | 2.97 | 23.2 Mil | Healthcare |